PERTH-BASED drug discovery company Phylogica has announced Canadian biotechnology firm, Axela Biosensors, will be testing its screening technology on Phylogica’s large pool of Phylomer drug candidates. The company said the drug candidates were selected because they represented a unique kind of small protein fragments known as peptides that have the potential to act as drugs by blocking a disease process at the protein level. Phylogica believes the collaboration is validation that its Phylomers are internationally recognised in this drug discovery area. The research collaboration with Alexa Biosensors is the eighth collaboration Phylogica has established in the past six months. Phylogica’s collaborations include McComb Foundation, John Hopkins University and Massachusetts General Hospital.
© Business News 2017. You may share content using the tools provided but do not copy and redistribute.